Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

GSK 1120212

Known as: GSK-1120212, GSK1120212, MEK Inhibitor GSK1120212 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
BACKGROUND KRAS mutations are detected in 25% of non-small-cell lung cancer (NSCLC) and no targeted therapies are approved for… Expand
  • table 1
  • table 2
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND This phase Ib trial investigated the safety, tolerability, and recommended phase II dose and schedule of the MEK… Expand
Is this relevant?
Highly Cited
2014
Highly Cited
2014
Purpose: MAPK and PI3K/AKT/mTOR pathways play important roles in many tumors. In this study, safety, antitumor activity, and… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2013
Highly Cited
2013
PURPOSE BRAF mutations promote melanoma cell proliferation and survival primarily through activation of MEK. The purpose of this… Expand
Is this relevant?
Review
2013
Review
2013
Myelodysplastic syndromes (MDS) are a group of hematologic disorders characterized by ineffective hematopoiesis that results in… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
2013
2013
Mutations of the oncogene KRAS are important drivers of pancreatic cancer progression. Activation of epidermal growth factor… Expand
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Recent results from clinical trials with the BRAF inhibitors GSK2118436 (dabrafenib) and PLX4032 (vemurafenib) have shown… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Purpose: Activating Q209L/P mutations in GNAQ or GNA11 (GNAQ/11) are present in approximately 80% of uveal melanomas. Mutant GNAQ… Expand
  • figure 1
  • figure 2
  • figure 4
  • figure 6
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Purpose: Despite their preclinical promise, previous MEK inhibitors have shown little benefit for patients. This likely reflects… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2011
Highly Cited
2011
CRA8503 Background: In preclinical models, the BRAF/MEK inhibitor (i) combination GSK436/GSK212 has demonstrated enhanced… Expand
Is this relevant?